HomeComparePSBKF vs ABBV

PSBKF vs ABBV: Dividend Comparison 2026

PSBKF yields 4.71% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $45.3K in total portfolio value
10 years
PSBKF
PSBKF
● Live price
4.71%
Share price
$0.67
Annual div
$0.03
5Y div CAGR
23.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.1K
Annual income
$9,483.50
Full PSBKF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — PSBKF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPSBKFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PSBKF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PSBKF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PSBKF
Annual income on $10K today (after 15% tax)
$400.51/yr
After 10yr DRIP, annual income (after tax)
$8,060.97/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $12,995.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PSBKF + ABBV for your $10,000?

PSBKF: 50%ABBV: 50%
100% ABBV50/50100% PSBKF
Portfolio after 10yr
$79.7K
Annual income
$17,127.63/yr
Blended yield
21.49%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PSBKF
No analyst data
Altman Z
0.1
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PSBKF buys
0
ABBV buys
0
No recent congressional trades found for PSBKF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPSBKFABBV
Forward yield4.71%3.06%
Annual dividend / share$0.03$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR23.6%40.6%
Portfolio after 10y$57.1K$102.3K
Annual income after 10y$9,483.50$24,771.77
Total dividends collected$31.8K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PSBKF vs ABBV ($10,000, DRIP)

YearPSBKF PortfolioPSBKF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,282$582.39$11,550$430.00$268.00ABBV
2$12,831$759.01$13,472$627.96$641.00ABBV
3$14,726$997.12$15,906$926.08$1.2KABBV
4$17,079$1,321.94$19,071$1,382.55$2.0KABBV
5$20,046$1,771.00$23,302$2,095.81$3.3KABBV
6$23,850$2,401.09$29,150$3,237.93$5.3KABBV
7$28,820$3,299.96$37,536$5,121.41$8.7KABBV
8$35,443$4,606.18$50,079$8,338.38$14.6KABBV
9$44,468$6,543.66$69,753$14,065.80$25.3KABBV
10$57,064$9,483.50$102,337$24,771.77$45.3KABBV

PSBKF vs ABBV: Complete Analysis 2026

PSBKFStock

Postal Savings Bank of China Co., Ltd., together with its subsidiaries, provides various banking products and services for retail and corporate customers in the People's Republic of China. Its Personal Banking segment offers savings products, such as demand, time, personal call, time/demand optional, and foreign currency deposits; passbooks; certificate of deposits; micro, personal pledged, and personal business loans; debit and credit cards; wealth management products and funds; and insurance agency services. This segment is also involved in distribution of fund products, electronic bonds, and precious metals; and provides payment and collection agency, various settlement, domestic remittance and exchange, cross-border remittance, personal exchange settlement and sale, and foreign currency exchange services. The company's Corporate Banking segment provides time, demand, call, and negotiated deposits; working capital, fixed asset, trade finance, stock pledge, land reserve, syndicated, real estate development, property mortgage, and consignment loans; cash management services; negotiable instruments; trade finance and international settlement services; and financial markets services. Its Treasury segment offers interbank lending transactions, repurchase and resale transactions, debt instrument investments, equity instrument investment, investment banking, bond securities, and wealth management products, etc., as well as trades in financial products comprising money market, fixed income, and foreign exchange products, as well as derivatives and precious metals. The company also provides online, mobile, and self-service banking services. As of December 31, 2021, it had 39,603 outlets, including 7,828 directly operated outlets and 31,775 agency outlets. The company was founded in 2007 and is headquartered in Beijing, the People's Republic of China. Postal Savings Bank of China Co., Ltd. is a subsidiary of China Post Group Corporation.

Full PSBKF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PSBKF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PSBKF vs SCHDPSBKF vs JEPIPSBKF vs OPSBKF vs KOPSBKF vs MAINPSBKF vs JNJPSBKF vs MRKPSBKF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.